IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: Impact on infliximab retreatment

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 10, 2015, Pages 1200-1208

  Fréling, Estelle ^a   Peyrin Biroulet, Laurent ^a   Poreaux, Claire ^a   Morali, Alain ^a   Waton, Julie ^a   Schmutz, Jean Luc ^a   Guéant, Jean Louis ^a   Barbaud, Annick ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

acute infusion reaction; anti infliximab antibodies; desensitization; IgE; immediate hypersensitivity; induction of tolerance; infliximab; skin tests

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DEXCHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; METHOTREXATE; ANTIIDIOTYPIC ANTIBODY; GASTROINTESTINAL AGENT; IMMUNOGLOBULIN E;

ADOLESCENT; ADULT; AGED; ALLERGY TEST; ARTICLE; CHILD; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DESENSITIZATION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INFUSION RATE; INFUSION RELATED REACTION; INTRACUTANEOUS TEST; MONOTHERAPY; NAUSEA; PRACTICE GUIDELINE; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RETREATMENT; SKIN TEST; SYSTEMIC THERAPY; ULCERATIVE COLITIS; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HYPERSENSITIVITY, IMMEDIATE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETREATMENT; SKIN TESTS; YOUNG ADULT;

EID: 84942040427     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000436     Document Type: Article

References (57)

1. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133:312-339.
2. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-1453.
3. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58:501-508.
4. Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol 2012; 39:1539-1545.
5. Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. J Rheumatol 2014; 41:1409-1415.
6. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, et al. A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4:221-256.
7. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315-1324.
8. Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ. Safety of infliximab in Crohns disease: a large single-center experience. Inflamm Bowel Dis 2010; 16:2109-2116.
9. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61:912-920.
10. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factoralpha antagonists. Curr Opin Allergy Clin Immunol 2007; 7:393-403.
11. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha- 1,3-galactose. N Engl J Med 2008; 358:1109-1117.
12. Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 2012; 159:321-326.
13. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusionrelated severe anaphylactic reactions. Allergy 2010; 65:657-661.
14. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohns disease. Clin Immunol 2006; 118:11-19.
15. Kato S, Kobayashi T, Kani K, Takabayashi H, Yamamoto R, Yakabi K. Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a Crohns disease patient. Inflamm Bowel Dis 2011; 17:E156-E157.
16. Vultaggio A, Matucci A, Nencini F, Pratesi S, Maggi E. Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. Intern Emerg Med 2012; 7:77-79.
17. Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013; 43:659-664.
18. Babouri A, Buisson A, Bigard MA, Peyrin-Biroulet L. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7:129-133.
19. Babouri A, Roblin X, Filippi J, Hébuterne X, Bigard MA, Peyrin- Biroulet L. Tolerability of one hour 10 mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. J Crohns Colitis 2014; 8:161-165.
20. Barbaud A, Granel F, Waton J, Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol 2011; 21:667-674.
21. Olszewski A, Pons L, Moutété F, Aimone-Gastin I, Kanny G, Moneret- Vautrin DA, Guéant JL. Isolation and characterization of proteic allergens in refined peanut oil. Clin Exp Allergy 1998; 28:850-859.
22. Guéant JL, Mata E, Namour F, Romano A, Aimone-Gastin I, Kanny G, et al. Criteria of evaluation and of interpretation of Sepharose drug IgERIA to anaesthetic drugs. Allergy 1999; 54:17-22.
23. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45-51.
24. Barbaud A, Gonalo M, Bruynzeel D, Bircher A. European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321-328.
25. Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cuttingedge therapies. Expert Rev Clin Immunol 2012; 8:43-52. quiz 53-54.
26. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009; 23:101-112.
27. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
28. Baert F, Noman M, Vermeire S, Van Assche G, D Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med 2003; 348:601-608.
29. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108:40-47.
30. OMeara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20:1-6.
31. Lelong J, Duburque C, Fournier C, Colombel JF, Desreumaux P, Tonnel AB, et al. Desensitisation to infliximab in patients with Crohns disease (in French). Rev Mal Respir 2005; 22:239.
32. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259-1266.
33. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68:702-712.
34. Hwang SH, Yoo HS, Yoon MK, Park HS. Detection of IgE binding component to infliximab in a patient with infliximab-induced anaphylaxis. Ann Allergy Asthma Immunol 2014; 112:393-394.
35. Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35:714-722.
36. Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohns disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109:1055-1064.
37. Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8:881-889.
38. Wee JS, Petrof G, Jackson K, Barker J, Smith CH. Infliximab for the treatment of psoriasis in the UK: 9 years experience of infusion reactions at a single centre. Br J Dermatol 2012; 167:411-416.
39. Vermeire S, Noman M, Van Assche G, Baert F, DHaens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease. Gut 2007; 56:1226-1231.
40. Duchesne C, Faure P, Kohler F, Pingannaud M-P, Bonnaud G, Devulder F, et al. Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists. Dig Liver Dis 2014; 46:675-681.
41. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34:51-58.
42. Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37:1172-1183.
43. Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, et al. The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60:41-48.
44. Uthman I, Touma Z, El-Sayyad J, Zaitoun F. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol 2006; 25:540-541.
45. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10:333-338.
46. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohns disease. Am J Gastroenterol 2004; 99:1984-1989.
47. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003; 30:2315-2318.
48. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004; 16: 627-630.
49. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohns disease. J Crohns Colitis 2012; 6:108-111.
50. Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol 2014; 12:1474.e2-1481.e2. quiz e91.
51. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial. Gastroenterology 2003; 124:917-924.
52. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64:1647-1649.
53. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004; 31:1912-1917.
54. Lahdenne P, Wikström AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res (Hoboken) 2010; 62:785-790.
55. Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:444-447.
56. Castells Guitart MC. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. J Investig Allergol Clin Immunol 2014; 24:72-79.
57. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al. Successful induction of tolerance to infliximab in patients with Crohns disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006; 24:851-858.